share_log

Johnson & Johnson's Janssen Unit Says Phase 2 Trial of Blood Disorder Drug Nipocalimab Meets Primary Endpoint

Johnson & Johnson's Janssen Unit Says Phase 2 Trial of Blood Disorder Drug Nipocalimab Meets Primary Endpoint

約翰遜詹森單位說血液障礙藥物尼泊卡利美抗的第二階段試驗達到主要終點
MT Newswires ·  2023/02/06 10:51

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論